THE STATUS AND MANAGEMENT OF MOOSE IN NORTH AMERICA - CIRCA 2015

Both declining and increasing moose (Alces alces) populations have been reported across North America over the last decade. We surveyed all jurisdictions with extant moose populations to determine the extent of these population trends. In 2014–2015, the North American moose population was estimated at ~1,000,000 animals distributed in 30 jurisdictions, which is unchanged since the turn of the century. Populations occurred in 12 Canadian provinces or territories, and in at least 18 states. In the past 5 years, moose density is believed to be increasing in 9, relatively stable in 8, and declining in 11 jurisdictions; estimates of change were unavailable in 2 jurisdictions. In 2014–2015, an estimated 425,537 licensed moose hunters harvested 82,096 moose in 23 jurisdictions. Hunter numbers increased by 39,118, whereas total harvest remained virtually unchanged from a decade earlier. Harvests by Indigenous and subsistence users, although largely unquantified, are believed substantial and important to quantify in certain jurisdictions. A variety of active and passive harvest strategies used to manage moose are discussed

THE STATUS AND MANAGEMENT OF MOOSE IN NORTH AMERICA - CIRCA 2015

Both declining and increasing moose (Alces alces) populations have been reported across North America over the last decade. We surveyed all jurisdictions with extant moose populations to determine the extent of these population trends. In 2014–2015, the North American moose population was estimated at ~1,000,000 animals distributed in 30 jurisdictions, which is unchanged since the turn of the century. Populations occurred in 12 Canadian provinces or territories, and in at least 18 states. In the past 5 years, moose density is believed to be increasing in 9, relatively stable in 8, and declining in 11 jurisdictions; estimates of change were unavailable in 2 jurisdictions. In 2014–2015, an estimated 425,537 licensed moose hunters harvested 82,096 moose in 23 jurisdictions. Hunter numbers increased by 39,118, whereas total harvest remained virtually unchanged from a decade earlier. Harvests by Indigenous and subsistence users, although largely unquantified, are believed substantial and important to quantify in certain jurisdictions. A variety of active and passive harvest strategies used to manage moose are discussed

SELECTIVE MOOSE HARVEST IN NORTH CENTRAL ONTARIO - A PROGRESS REPORT

Ontario introduced a province-wide sex and age selective harvest strategy for moose (Alces alces) in 1983. The program was designed to double the provincial moose population by the year 2000 by controlling the annual hunter harvest of bulls and cows in 67 Wildlife Management Units (WMU’s). In north-central Ontario the harvest sex/age ratio has averaged 54% bulls, 28% cows and 18% calves in 14 WMU's after eight years. A step-wise increase In the calf kill and corresponding decrease in the cow kill has occurred. There appears to be a trend towards a higher proportion of breeders and a lower proportion of yearlings and teens in both the adult bull and cow harvest. Demand for adult tags and success rates continues to increase in many WMU's as hunters report seeing more moose. Aerial inventories since 1983 suggest that populations in WMU's west of Lake Nipigon have generally reached or exceeded year 2000 targets while those to the east have failed to respond. Data for two WMU's, one representing a population response and the other, relative population stability are analyzed and discussed. Population densities in these WMU's are believed related, in part to differences in winter severity and land capability. Densities in both have declined slightly since 1988 as current mortality rates from all sources exceed annual recruitment. Adjacent jurisdictions (Isle Royale and northeastern Minnesota) display similar trends to several adjoining WMU's, regardless of density, hunter harvest or the presence or absence of white-tailed deer (Odocoileus virginianus). Increased winter tick (Dermacentor albipictus) mortality, triggered by short-term changes in weather patterns in the late 1980’s, is believed responsible for synchronous population declines in northeastern Minnesota and on Isle Royale. It is possible that ticks were also involved in similar declines seen in WMU’s 11B, 13 and 14, although the evidence is circumstantial. We recommend current WMU population and harvest targets to be reviewed and adjusted to land capability; that lower and more flexible harvest rates will be tailored to sustain and local populations, and that further research on weather-related population changes can be undertaken

Developing a woodland caribou habitat mosaic on the Ogoki-Nakina North Forests of northwestern Ontario

The Ogoki-North Nakina Forests consist of (10 638 km2) unroaded boreal forest approximately 400 km northeast of Thunder Bay, Ontario (lat 50°- 51°31'N, long 86°30'- 89°W). Woodland caribou (Rangifer tarandus caribou) inhabit discrete portions within these forests based on minimal current and past historical data. As part of the Forest Management Planning process, for the period 1997-2097, a woodland caribou habitat mosaic has been developed to coordinate present and future forest management activities with the retention and development of current and future woodland caribou habitat. Several criteria including, past fire history, forest structure, age, species composition, proximity to current road access and location of existing and potential caribou habitat, helped identify and delineate 50 mosaic harvest blocks. Each harvest block will be logged in one of five 20 year periods over a 100 year rotation (1997¬2097). The harvest blocks have been developed to simulate a pattern of past wildfire history in an area that has not been subjected to past forest management activities, while managing for woodland caribou, a locally featured species

Supplementary Material for: Associations between Exposure to Persistent Organic Pollutants in Childhood and Overweight up to 12 Years Later in a Low Exposed Danish Population

<b><i>Background: </i></b>Persistent organic pollutants (POPs) have metabolic disrupting abilities and are suggested to contribute to the obesity epidemic. We investigated whether serum concentrations of POPs at 8-10 years of age were associated with subsequent development of overweight at age 14-16 and 20-22 years. <b><i>Methods: </i></b>The study was based on data from the European Youth Heart Study, Danish component (1997). Concentrations of several polychlorinated biphenyls (PCBs) and the organochlorine pesticides p,p-dichlorodiphenyldichloroethylene (DDE) and hexachlorobenzene (HCB) were measured in serum from children aged 8-10 years (n = 509). Information on BMI z-scores, waist circumference and % body fat were collected at clinical examinations at ages 8-10, 14-16 and 20-22 years. Multiple linear regression analyses were performed taking potential confounders into account. <b><i>Results: </i></b>Overall, POP serum concentrations were low: median ΣPCB 0.18 µg/g lipid, DDE 0.04 µg/g lipid and HCB 0.03 µg/g lipid. POPs were generally not associated with weight gain at 14-16 and 20-22 years of age, except for an inverse association among the highest exposed girls at 20-22 years of age, which might possibly be explained by multiple testing or residual confounding. <b><i>Conclusion: </i></b>This study suggests that, in a low exposed population, childhood serum concentrations of PCB, DDE, and HCB are not associated with subsequent weight gain

Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial

BACKGROUND: Local treatment of pelvic Ewing's sarcoma may be challenging, and intergroup studies have focused on improving systemic treatments rather than prospectively evaluating aspects of local tumor control. The Euro-EWING99 trial provided a substantial number of patients with localized pelvic tumors treated with the same chemotherapy protocol. Because local control included surgical resection, radiation therapy, or a combination of both, we wanted to investigate local control and survival with respect to the local modality in this study cohort. QUESTIONS/PURPOSES: (1) Do patients with localized sacral tumors have a lower risk of local recurrence and higher survival compared with patients with localized tumors of the innominate bones? (2) Is the local treatment modality associated with local control and survival in patients with sacral and nonsacral tumors? (3) Which local tumor- and treatment-related factors, such as response to neoadjuvant chemotherapy, institution where the biopsy was performed, and surgical complications, are associated with local recurrence and patient survival in nonsacral tumors? (4) Which factors, such as persistent extraosseous tumor growth after chemotherapy or extent of bony resection, are independently associated with overall survival in patients with bone tumors undergoing surgical treatment? METHODS: Between 1998 and 2009, 1411 patients with previously untreated, histologically confirmed Ewing's sarcoma were registered in the German Society for Pediatric Oncology and Hematology Ewing's sarcoma database and treated in the Euro-EWING99 trial. In all, 24% (339 of 1411) of these patients presented with a pelvic primary sarcoma, 47% (159 of 339) of which had macroscopic metastases at diagnosis and were excluded from this analysis. The data from the remaining 180 patients were reviewed retrospectively, based on follow-up data as of July 2016. The median (range) follow-up was 54 months (5 to 191) for all patients and 84 months (11 to 191) for surviving patients. The study endpoints were overall survival, local recurrence and event-free survival probability, which were calculated with the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) with their respective 95% CIs were estimated in a multivariate Cox regression model. RESULTS: Sacral tumors were associated with a reduced probability of local recurrence (12% [95% CI 1 to 22] versus 28% [95% CI 20 to 36] at 5 years, p = 0.032), a higher event-free survival probability (66% [95% CI 51 to 81] versus 50% [95% CI 41 to 58] at 5 years, p = 0.026) and a higher overall survival probability (72% [95% CI 57 to 87] versus 56% [95% CI 47 to 64] at 5 years, p = 0.025) compared with nonsacral tumors. With the numbers available, we found no differences between patients with sacral tumors who underwent definitive radiotherapy and those who underwent combined surgery and radiotherapy in terms of local recurrence (17% [95% CI 0 to 34] versus 0% [95% CI 0 to 20] at 5 years, p = 0.125) and overall survival probability (73% [95% CI 52 to 94] versus 78% [95% CI 56 to 99] at 5 years, p = 0.764). In nonsacral tumors, combined local treatment was associated with a lower local recurrence probability (14% [95% CI 5 to 23] versus 33% [95% CI 19 to 47] at 5 years, p = 0.015) and a higher overall survival probability (72% [95% CI 61 to 83] versus 47% [95% CI 33 to 62] at 5 years, p = 0.024) compared with surgery alone. Even in a subgroup of patients with wide surgical margins and a good histologic response to induction treatment, the combined local treatment was associated with a higher overall survival probability (87% [95% CI 74 to 100] versus 51% [95% CI 33 to 69] at 5 years, p = 0.009), compared with surgery alone.A poor histologic response to induction chemotherapy in nonsacral tumors (39% [95% CI 19 to 59] versus 64% [95% CI 52 to 76] at 5 years, p = 0.014) and the development of surgical complications after tumor resection (35% [95% CI 11 to 59] versus 68% [95% CI 58 to 78] at 5 years, p = 0.004) were associated with a lower overall survival probability in nonsacral tumors, while a tumor biopsy performed at the same institution where the tumor resection was performed was associated with lower local recurrence probability (14% [95% CI 4 to 24] versus 32% [95% CI 16 to 48] at 5 years, p = 0.035), respectively.In patients with bone tumors who underwent surgical treatment, we found that after controlling for tumor localization in the pelvis, tumor volume, and surgical margin status, patients who did not undergo complete (defined as a Type I/II resection for iliac bone tumors, a Type II/III resection for pubic bone and ischium tumors and a Type I/II/III resection for tumors involving the acetabulum, according to the Enneking classification) removal of the affected bone (HR 5.04 [95% CI 2.07 to 12.24]; p < 0.001), patients with a poor histologic response to induction chemotherapy (HR 3.72 [95% CI 1.51 to 9.21]; p = 0.004), and patients who did not receive additional radiotherapy (HR 4.34 [95% CI 1.71 to 11.05]; p = 0.002) had a higher risk of death. The analysis suggested that the same might be the case in patients with a persistent extraosseous tumor extension after induction chemotherapy (HR 4.61 [95% CI 1.03 to 20.67]; p = 0.046), although the wide CIs pointing at a possible sparse-data bias precluded any definitive conclusions. CONCLUSION: Patients with sacral Ewing's sarcoma appear to have a lower probability for local recurrence and a higher overall survival probability compared with patients with tumors of the innominate bones. Our results seem to support a recent recommendation of the Scandinavian Sarcoma Group to locally treat most sacral Ewing's sarcomas with definitive radiotherapy. Combined surgical resection and radiotherapy appear to be associated with a higher overall survival probability in nonsacral tumors compared with surgery alone, even in patients with a wide resection and a good histologic response to neoadjuvant chemotherapy. Complete removal of the involved bone, as defined above, in patients with nonsacral tumors may be associated with a decreased likelihood of local recurrence and improved overall survival. Persistent extraosseous tumor growth after induction treatment in patients with nonsacral bone tumors undergoing surgical treatment might be an important indicator of poorer overall survival probability, but the possibility of sparse-data bias in our cohort means that this factor should first be validated in future studies. LEVEL OF EVIDENCE: Level III, therapeutic study